Loading
Loading
Review of Case Materials
Reviews records, documents, testimony, data, and other relevant materials and consults with counsel regarding technical issues related to the matter.
Provide Expert Analysis
Applies specialized knowledge and experience to evaluate the technical or professional issues involved.
Form Expert Opinions
Develops independent, supportable opinions based on the available evidence and relevant standards.
Prepare Expert Reports
Showing Results 0 of 0
No. PSA is produced by both normal and malignant prostate cells, and an elevated level can occur with prostate cancer as well as benign prostatic enlargement, prostatitis, and other conditions. A PSA result may prompt repeat testing, imaging, biopsy, or other evaluation, but the value and its trend should be interpreted with the clinical findings and other diagnostic evidence.
A pathologist evaluates the microscopic growth patterns of prostate cancer and assigns Gleason patterns that are combined into a Gleason score. The corresponding Grade Group ranges from 1 through 5, with higher groups generally associated with more aggressive biological behavior. Grade Group, PSA level, tumor extent, lymph-node status, and metastatic findings can contribute to staging, prognosis, risk assessment, and treatment planning.
Active surveillance closely monitors selected prostate cancers while delaying surgery, radiation, or another definitive treatment unless evidence suggests clinically important progression. Follow-up may include PSA testing, clinical assessment, prostate MRI, and repeat biopsy according to the surveillance protocol and patient circumstances. Unlike watchful waiting, active surveillance is intended to preserve the option of treatment with curative intent if the cancer shows concerning change.
Management depends on the stage and risk characteristics of the cancer, including PSA, Grade Group, tumor extent, lymph-node involvement, metastatic disease, and other pathological or imaging findings. Age, overall health, life expectancy, prior treatment, anticipated treatment effects, and patient preferences can also affect the options considered. Localized, locally advanced, recurrent, and metastatic prostate cancers can therefore follow substantially different treatment pathways.
Prepares clear, well-supported expert reports outlining methodology, analysis, findings, and opinions.
Provide Deposition Testimony
Explains findings and opinions under oath and responds to questioning during deposition testimony.
Testify in Court
Presents specialized findings and opinions clearly to judges, juries, arbitrators, or other decision-makers.
A rising PSA can be an early sign of persistent or recurrent prostate cancer, sometimes before disease is visible on imaging or causes symptoms, but one elevated measurement does not necessarily establish recurrence. After radical prostatectomy, PSA is expected to fall to a very low or undetectable level, and biochemical recurrence is commonly defined using a PSA threshold of at least 0.2 ng/mL, with the trend and confirmation interpreted according to the applicable guideline and clinical circumstances. After radiation therapy, PSA declines more gradually, and biochemical recurrence is commonly defined as an increase of 2 ng/mL above the post-treatment PSA nadir. Subsequent PSA measurements, PSA kinetics, imaging, pathology when applicable, and the prior disease and treatment history help determine the significance of the rise.
